PFE — Pfizer Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapSuper Stock

Annual income statement for Pfizer, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	C2022 December 31st	C2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	8-K
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	81,288	101,175	59,554	63,627	62,579
Cost of Revenue
Gross Profit	50,602	67,078	41,765	47,295	47,439
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	57,802	64,310	60,483	54,020	52,924
Operating Profit	23,486	36,865	-929	9,607	9,655
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	24,311	34,729	1,058	8,023	7,520
Provision for Income Taxes
Net Income After Taxes	22,459	31,401	2,173	8,051	7,786
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	21,980	31,372	2,119	8,031	7,770
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	21,979	31,372	2,119	8,031	7,771
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	5.12	5.86	2.46	2.2	3.67
Dividends per Share